<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746693</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-291012</org_study_id>
    <nct_id>NCT01746693</nct_id>
  </id_info>
  <brief_title>Neurovascular Coupling in Subjects With Amblyopia</brief_title>
  <official_title>Neurovascular Coupling in Subjects With Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amblyopia is a developmental condition that is characterized by reduced vision of the eye due&#xD;
      to the presence of a sensory impediment during visual development, such as strabismus (ocular&#xD;
      misalignment) or anisometropia (unequal refractive error), occurring early in life. Recent&#xD;
      studies in humans and animals point towards a cortical locus for the processing deficit in&#xD;
      amblyopia, revealing sensory deficits at the signal cell level. If changes in retinal&#xD;
      neuronal function are also present, is unknown.&#xD;
&#xD;
      Like in the brain, blood flow in the retina is coupled to neuronal activity. This phenomenon&#xD;
      has been measured by different study groups with non invasive techniques in the brain and&#xD;
      retina. It has been shown in previous studies that stimulating the retina with diffuse&#xD;
      luminant flickering light increases retinal vessel diameter and blood flow. However, it is&#xD;
      unknown whether this is also the case in the retina of amblyopic eyes. Additionally, the&#xD;
      introduction of blood oxygen level dependent (BOLD) fMRI also makes it possible to directly&#xD;
      access the vascular response in the brain to visual stimuli.&#xD;
&#xD;
      Therefore, the aim of the present study is to investigate the effect of luminant flickering&#xD;
      light on retinal vessel diameter and retinal blood flow in subjects with amblyopia. Also,&#xD;
      oxygen saturation in retinal vessels will be assessed as well as pattern ERG for assessment&#xD;
      of retinal function. Additionally, a high resolution image of the visual pathway will be&#xD;
      taken with 7 Tesla MRI to investigate whether anatomical or functional alterations are&#xD;
      present.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">September 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Vessel Diameter in Response to Flickering Light (DVA)</measure>
    <time_frame>once on the study day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal (arterial and venous) oxygen saturation</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal blood velocity in response to flickering light</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High resolution functional and anatomical imaging of the visual pathway</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inner Retinal Function</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amblyopia ex Strabismus</condition>
  <condition>Amblyopia ex Anisometropia</condition>
  <arm_group>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 male and female volunteers with amblyopia ex anisometropia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 male and female volunteers with amblyopia ex strabismus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy male and female control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Vessel Analyzer</intervention_name>
    <description>retinal vessel diameter, retinal oxygen saturation</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Velocimetry</intervention_name>
    <description>retinal blood flow velocity, retinal blood flow</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7-Tesla MRI</intervention_name>
    <description>High resolution functional and anatomical imaging of the visual pathway</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pattern electroretinography</intervention_name>
    <description>inner retinal function</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fourier domain optical coherence tomography</intervention_name>
    <description>Blood flow in retina.</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 18 and 55 years&#xD;
&#xD;
          -  Non-smokers (for at least 6 months)&#xD;
&#xD;
          -  Normal findings in the medical history and physical examination unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant&#xD;
&#xD;
          -  Normal ophthalmic findings except amblyopia on one eye resulting from anisometropia or&#xD;
             strabismus with a visual acuity of Snellen ≤ 0.3 with best correction on the amblyopic&#xD;
             eye and Snellen 0.9 or better in the contralateral eye (for subjects with amblyopia)&#xD;
&#xD;
          -  Normal ophthalmic findings with visual acuity of Snellen ≥ 1.0 in both eyes (for&#xD;
             control subjects)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Presence or history of a severe medical condition as judged by the clinical&#xD;
             investigator&#xD;
&#xD;
          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical&#xD;
             trial in the 3 weeks preceding the study (except oral contraceptives)&#xD;
&#xD;
          -  Blood donation during the previous three weeks&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
&#xD;
          -  Any metallic, electric, electronic or magnetic device or object not removable except&#xD;
             dental fillings&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Epilepsia, history or family history of seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>2981</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>2981</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>retinal vessel diameter</keyword>
  <keyword>retinal oxygen saturation</keyword>
  <keyword>high resolution functional and anatomical imaging</keyword>
  <keyword>inner retinal function</keyword>
  <keyword>flicker response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Anisometropia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

